{"retracted":false,"update":{"timestamp":1311638400000,"doi":"10.1007/s10637-011-9713-6","type":"correction"},"doi":"10.1007/s10637-011-9687-4","journal":"Investigational New Drugs","publisher":"Springer Nature","title":"Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy"}
